KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accounts Payables (2018 - 2025)

Historic Accounts Payables for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $77.5 million.

  • Esperion Therapeutics' Accounts Payables rose 12232.96% to $77.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 12232.96%. This contributed to the annual value of $51.6 million for FY2024, which is 6284.13% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Accounts Payables is $77.5 million, which was up 12232.96% from $74.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Accounts Payables ranged from a high of $77.5 million in Q3 2025 and a low of $12.8 million during Q2 2022
  • For the 5-year period, Esperion Therapeutics' Accounts Payables averaged around $35.0 million, with its median value being $28.4 million (2024).
  • Per our database at Business Quant, Esperion Therapeutics' Accounts Payables plummeted by 6621.65% in 2021 and then skyrocketed by 15320.58% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Accounts Payables stood at $17.6 million in 2021, then skyrocketed by 31.21% to $23.0 million in 2022, then soared by 37.66% to $31.7 million in 2023, then surged by 62.84% to $51.6 million in 2024, then surged by 50.07% to $77.5 million in 2025.
  • Its Accounts Payables stands at $77.5 million for Q3 2025, versus $74.7 million for Q2 2025 and $72.0 million for Q1 2025.